Leptomeningeal carcinomatosis, an emerging disease in internal medicine departments with a generally poor prognosis: two case reports

被引:0
作者
Pietrantonio, Filomena [1 ]
Lordi, Margherita [1 ]
Vinci, Fabio [1 ]
Alessi, Elena [1 ]
Pascucci, Matteo [1 ]
Castelli, Michela Delli [1 ]
Vinci, Antonio [2 ]
Cipriano, Enrica [1 ]
Rosiello, Francesco [3 ]
Ciamei, Angela [1 ]
机构
[1] ASL Roma 6, Osped Castelli, UOC Med Interna, I-00040 Ariccia, Italy
[2] ASL Roma 1, Osped S Spirito, Direz Sanit, Rome, Italy
[3] Sapienza Univ Rome, Dept Infect Dis & Publ Hlth, Rome, Italy
关键词
leptomeningeal carcinomatosis; internal medicine; breast cancer; comorbidities; complex patient; METASTATIC CARCINOMA; BREAST-CANCER; METHOTREXATE;
D O I
10.4081/itjm.2024.1727
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
As a result of improved diagnostic methods and higher cancer patient survival rates, leptomeningeal carcinomatosis is being found in internal medicine departments more frequently. Melanoma, lung cancer, and breast adenocarcinoma are the three cancers that are most commonly associated. When the main tumor diffuses through the bloodstream, cerebrospinal fluid, or direct diffusion and causes multiple focal neurological symptoms, it is known as leptomeningeal involvement; the prognosis is usually not good. Despite multimodal treatment, leptomeningeal carcinomatosis is an advanced form of cancer that frequently results in rapid death. Treatment is typically palliative and consists primarily of intrathecal or systemic radiation and/or chemotherapy. New experimental therapies and immunotherapy are promising means of lowering morbidity and mortality. Clinical cases of leptomeningeal carcinomatosis are reported; both cases were identified at the Ospedale dei Castelli's Department of Internal Medicine and resulted from primary breast pathology.
引用
收藏
页数:5
相关论文
共 10 条
[1]   Leptomeningeal Carcinomatosis Molecular Landscape, Current Management, and Emerging Therapies [J].
Bhambhvani, Hriday P. ;
Rodrigues, Adrian J. ;
Umeh-Garcia, Maxine C. ;
Gephart, Melanie Hayden .
NEUROSURGERY CLINICS OF NORTH AMERICA, 2020, 31 (04) :613-625
[2]   INTRATHECAL CYTOSTATIC CHEMOTHERAPY OF MENINGITIS CARCINOMATOSA - CLINICAL MANIFESTATION AND CEREBROSPINAL-FLUID CYTOLOGY IN A CASE OF METASTATIC CARCINOMA OF BREAST [J].
DOMMASCH, D ;
PRZUNTEK, H ;
GRUNINGER, W ;
MERTENS, HG .
EUROPEAN NEUROLOGY, 1976, 14 (03) :178-191
[3]  
Fizazi K, 1996, CANCER-AM CANCER SOC, V77, P1315, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1315::AID-CNCR14>3.0.CO
[4]  
2-4
[5]   Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab [J].
Kordbacheh, T. ;
Law, W. Y. ;
Smith, I. E. .
BREAST, 2016, 26 :54-58
[6]  
MCKELVEY EM, 1968, CANCER-AM CANCER SOC, V22, P576, DOI 10.1002/1097-0142(196809)22:3<576::AID-CNCR2820220313>3.0.CO
[7]  
2-C
[8]   INTRATHECAL ADMINISTRATION OF I-131 RADIOLABELED MONOCLONAL-ANTIBODY AS A TREATMENT FOR NEOPLASTIC MENINGITIS [J].
MOSELEY, RP ;
DAVIES, AG ;
RICHARDSON, RB ;
ZALUTSKY, M ;
CARRELL, S ;
FABRE, J ;
SLACK, N ;
BULLIMORE, J ;
PIZER, B ;
PAPANASTASSIOU, V ;
KEMSHEAD, JT ;
COAKHAM, HB ;
LASHFORD, LS .
BRITISH JOURNAL OF CANCER, 1990, 62 (04) :637-642
[10]   Leptomeningeal metastasis from systemic cancer: Review and update on management [J].
Wang, Nancy ;
Bertalan, Mia S. ;
Brastianos, Priscilla K. .
CANCER, 2018, 124 (01) :21-35